Member Info for sadoldgit

I were just about to post that this application must put at least half a penny on a share at least.

Ahfam, we are at 0.7p already, I trust you mean £0.10 or 10p. I just woke up as had a bit of a night mare. Sar SP price at 11.1??p. But I had no shares.

Fearg, that is very likely given that viruses spread in cold damp weather with very little UV light.

I just did 350k just after 8 am

just nudging 7 million, None in an ISA

Interesting paragraph with regards to treatment of Covid-19 induces cytokenes. Many big pharmas pushing the auto immune treatments for arthritis as a big this is the one be all cure. They have millions of pounds to push their products into trials using their dated first generation Kinase inhibitors with know and sometimes serious side effects.

FLT3 Kinase
Sareum has used its SKIL platform to develop a novel chemical series that inhibits the activity of FLT3 kinase and is highly selective against a panel of other kinases. These have potential use against certain types of leukaemia as well as autoimmune disorders such as Rheumatoid Arthritis and Multiple Sclerosis.
if I remember correctly FLT was extremely well tolerated.
As an addition to the above there is plenty of space for Tyk2. It will be some time before an effective treatment for Covid-19 becomes available. It it right to push old first generation treatments with known side effects as against later enhanced more targeted 2nd generation inhibitors with as yet no known side effects and very high ( in the case of tyk2 no mtd) doseage levels.
The website is updated I would hazard a guess due to Tims Bio trinity video conference. The conference lasted a few minutes but the information and potential that it contained was phenomenal. So much in such a short space of time. It is really only properly understood by people involved in that aspect of science and biology. Note a scientist is not a salesman and does not use buzzwords. It works or it does not.
The Chinese are not innovative have extremely poor quality control, but for sure they are not fools. I for one look forward to updates on FLT with the Chinese.

Good news for Sorrento however, as their SP is up circa 150%

The word 'appears' is used. The question is does it work in human patients or not and what side effects does it have? Will it affect the bodies immune system ie risk of infection? They will not know that for at least another 3 months at least.
200 litres for 100k people (2ml per person).
How does it affect Sar you ask?
In my own opinion, it not likely to have much effect. There will never be one solution fits all. Tyk2 would appear a good candidate for Covid-19 but its primary intention for use is for one compound in oncology and one compound in auto immune diseases and this claim of 100 % by Sorrento, whether it works or whether it does not changes nothing at all.
Regards

Try looking at the deal at a different angle. Sareum are low on funds. Not desperate but low. To conserve money the Bod have taken a pay cut. As another possible line to gain funds of 900k payment in 6 months time the Bod have licensed to a China pharma ( on the successful production of FLT+3 compounds) hence the low upfront payment. In this case beggars can't be choosers so as to speak.
If the board did not take a pay cut, did not license, it is very likely additional funding would need to be raised via a placement. For the funding required and the placement value per share, considerable dilution would take place which would severely pi55 investors off.
it is not inconceivable to conclude that Sareum have placed significant value on their Tyk2 Jak 1 kinase inhibitor. That is the most important compound that Sareum have and they will not be letting that go for next to nothing to appease a few shareholders. Yes, a lot of us get peeved at times.
Do you yourself think it would have been better for Sareum not to have let this go to a China Pharma by wanting a bigger upfront payment with the almost inevitable SP dilution, or ending up risk giving away their Tyk2 jewel in the crown?
Put a price on Tyk 2. How much is it worth regardless of Covid-19? How much is it worth if it is a viable treatment for Covid-19? It is a new class 2nd generation kinase inhibitor without ( as far as we know at the moment) nasty side effects.
How much does a buyer put up front? At what stage do milestone payments become payable? How much and at what stage are the milestone payments made? This takes time to negotiate/compromise and resolve. Some here may be happy for 2 to 3p a share, some 5 to 10 p a share and some who will hold for 25p plus a share. If you were a board Director which of the investors would you aim to satisfy? Do you let it go for the least you can get in a hastily put together deal or achieve the best deal possible?
Some will be of the opinion that as an investor enough is must be break even/ get their money back plus a little bit. Yes there will be many? But there also lies the other side of the coin, there are some very heavily invested people here who own more shares than many 10's of investors put together. If you were a director of a company which has investors, whom do you aim to satisfy?
To summarise, all Sareum are doing is protecting the best deal that they can secure for their compound.
This is my opinion and of course you will have your own opinions too.
Oh, nearly forgot, dyor.
Regards

I think you may be right there Gekgo. I will endeavour to look further.

25/03/2016 · Donggang Liu, an associate professor in the Computer Science and Engineering Department, passed away March 20 at Baylor Medical Center in Dallas, after a long and courageous battle with brain cancer. His wife and parents, who had arrived from China on Friday, were with him.

If you go to the article in question and copy the text that you want, then search Mandarin to English and select Mandarin to English you can paste your copy in the required space and the resultant translation is shown next to it.

Best I can do on first part :- Yan Jiangdong, Wang Yinghui, Wan Yue (Chongqing University Affiliated Oncology Hospital / Chongqing Cancer Research Institute / Chongqing Cancer Hospital Oncology Radiotherapy Center, Chongqing 400030)
Key words: tumors; inhibitors; DNA damage repair; genes
Human cells produce a large number of different types of damage every day under the action of internal and external source DNA damage factors, and human cells also have a sound DNA repair mechanism to deal with these damage, restore the integrity and fidelity of DNA, so as to maintain genetic stability. There is growing evidence that DNA repair function changes during tumor occurrence, development, and treatment, and these changes are likely to be closely related to the various biological behaviors of tumors. Many carcinogens cause mutations in genes through damage to genomic DNA, and once key genes in the DNA damage response (DDR) pathway, such as BRCA1, BRCA2, BLM, FANCA, TP53, RAD51C and MSH2, mutate, can further lead to DNA repair functional defects and lead to genomic instability, which can easily increase the risk of cancer. Tumor cells carry a large number of mutant genes, DNA replication will produce a replication fork block that triggers DDR causes apoptosis, when the redox reaction-related genes are inactivated in a mutant state, oxidative stress produced by the reactive oxygen free radicals (ROS) can cause DNA oxidation damage. Therefore, we can use DNA repair inhibitors to amplify the effects of DNA replication stress and oxidative stress, to push through the limits of tumor cells' tolerance to these effects, and ultimately to produce irreversible DNA damage and lead to tumor cell death. This paper summarizes the current clinical research status of various DNA repair inhibitors, and summarizes the necessity of screening therapeutic prediction markers and the feasibility of exploring new joint treatment strategies.

The true scale of the corona virus is only just coming to light:- https://www.msn.com/en-gb/news/coronavirus/as-coronavirus-overruns-russia-doctors-are-dying-on-the-front-lines/ar-BB1480lB?ocid=spartandhp

Spot on Andy. Tim and co been in discussions long before Covid-19 came into existence. I still say we have an excellent compound with Tyk 2 as is a second generation Tyk 2 Jak 1 compound. If anything a Covid-19 will result in delays concluding a possible/probable contract. As Tim pointed out in his video conference they can obtain the compounds in the 100's of grammes capabilities.
Chk 1 is pretty will top class too as is Aurora FLT+3 ( but requires precise manufacturing of the compound for lab and trials)
Onwards and upwards.

Have a look at the following :- https://the-cma.org.uk/Articles/Cytokine-storm-syndrome-how-to-stop-it-6285/
Look under 'Dangers'
Area of origination of cytokines is the targeted areas of Sareums FLT+3
Look up Anakira ( now being used in trials with 240 people. Old drug first approved in the US in 2001. Has some bad side effects too
I wont rabbit on as this 7 th and very short version then the screen freezes and I lose the lot.
But yes worth a read.

I would hazard a guess and say yes it can be made to be taken intravenously, as it is much harder to make an orally available compound than an IV compound. The whole idea of the oral route was that you would not have to attend hospital for it to be administered. Since you would be in hospital and most likely not in a fit state, plus the addition to nausea with a good chance of you vomting it up with a risk of choking then IV would certainly be the most appropriate route. I am sure Sareum have that well in their grasp should the need arrive.
Interesting point their krone of great importance.

Tim did state that they have the facilities to produce 100's of grammes in his Bio Trinity conference video. Much of what he says is so easily missed.

Only TYK 2 Jak1 compound too. No maximum tolerated dose established and this has been tested at 30 times dosage levels. No Jak 2 or 3 and its attributed black box warning of serious effects. Trust in the science.

Spot on with Tim, There really is not much he can put in an RNS without giving the game away and I certainly do not see him doing that as he got lambasted for his expectations in Dec 2012.
Once it is in the box then we will get an RNS. Until then one long waiting game.
Good for you to have a top up, it is irrelevant of size. I sincerely hope one day in the not too distant future all holders long term and not so long term will be rewarded.
Regards